Skin care claims
Estee Lauder is seeking declaratory relief from FDA on skin care claims for five of the seven products cited by a 1987 regulatory letter for making unapproved new drug claims. Filed Sept. 23 in D.C. District Court, the suit is an attempt to prevent FDA from taking any further regulatory action against the company until the case has been heard. A hearing has not yet been set. Estee Lauder names as plaintiffs in the suit FDA Commissioner Young and Associate Commissioner for Regulatory Affairs John Taylor.
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.